.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX09_Nintedanib.Nintedanib

Information

Nintedanib is an oral tyrosine kinase inhibitor used primarily for the treatment of idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and as an adjunct therapy for some cancers such as non-small cell lung cancer (NSCLC). It is approved for use in numerous countries, including by the US FDA and EMA.

Pharmacokinetics

Pharmacokinetic parameters were reported in adult patients (both sexes) with idiopathic pulmonary fibrosis after single and multiple oral doses.

References

1. Schmid, U, et al., & Freiwald, M (2018). Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis. Cancer chemotherapy and pharmacology 81(1) 89–101. DOI:10.1007/s00280-017-3452-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29119292

2. Daga, H, et al., & Nakagawa, K (2015). Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer. Cancer chemotherapy and pharmacology 76(6) 1225–1233. DOI:10.1007/s00280-015-2896-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26560486

3. Van Cutsem, E, et al., & Capdevila, J (2015). A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology 26(10) 2085–2091. DOI:10.1093/annonc/mdv286 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26272806

Revisions

• 06/2025 initial generated model